Free Trial
NYSE:PLX

Protalix BioTherapeutics 3/14/2024 Earnings Report

Protalix BioTherapeutics logo
$1.59 +0.03 (+1.92%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.63 +0.04 (+2.52%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.03
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Protalix BioTherapeutics Revenue Results

Actual Revenue
$10.49 million
Expected Revenue
$8.15 million
Beat/Miss
Beat by +$2.34 million
YoY Revenue Growth
N/A

Protalix BioTherapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Protalix BioTherapeutics Earnings Headlines

Analysts Issue Forecasts for PLX Q1 Earnings
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
PLX: First Quarter Results
See More Protalix BioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protalix BioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protalix BioTherapeutics and other key companies, straight to your email.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX), a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

View Protalix BioTherapeutics Profile

More Earnings Resources from MarketBeat